This review highlights the potential of lipidomic and metabolomic biomarkers in predicting breast cancer prognosis and therapy response, enhancing patient care.
Bain-backed Cardurion raises $260M to fund ex-Imara drug, buy more cardio assets
Cardurion Pharmaceuticals is going shopping for more cardio drug candidates. The Burlington, MA-based biotech, which launched in 2017 with a Sign up to read this